ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

roxadustat

Also written as “Roxadustat”, “FG-4592” and “ASP1517”.

Its studies are mostly in Anemia · Renal Insufficiency, Chronic · Kidney Failure, Chronic · Myelodysplastic Syndromes · Renal Insufficiency, led by 3 companies.

Drug pageRoxadustat: every studyAll 63 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jun 25, 201347 company-led studies, 2 open or runningNext primary completion: Oct 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Astellas Pharmaits history only221 open or runningphase 3since Jun 25, 2013Sep 15, 2009Oct 30, 2027phase 3 · NCT05970172
Kyntra Bioits history only221 open or runningphase 4since Aug 8, 2019Sep 25, 2008Sep 2030phase 3 · NCT07722988
AstraZeneca30 open or runningphase 4since Dec 3, 2020Jun 24, 2014none ahead

Also a collaborator on its studies: Parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AstraZeneca only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 24, 2014First studies: 2 phase 3 studies in AnemiaFirst studyNCT02174731, NCT02174627
  2. Dec 3, 2020Phase 4 study in Renal Insufficiency, ChronicNCT04655027 · 25 enrolled · China

TargetBeta

“Hypoxia-inducible factor prolyl hydroxylase inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
daprodustatruleGlaxoSmithKlinephase 333

Studies

All 3 AstraZeneca leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04655027Renal Insufficiency, Chronic · China4CompletedOct 12, 202125
NCT02174731Anemia · United States, Australia, Bulgaria and more3CompletedSep 26, 20182,133
NCT02174627Anemia · United States, Argentina, Brazil and more3CompletedOct 4, 20182,781

How it is read

Names in the registry

  • “Roxadustat”, 25 entries
  • “FG-4592”, 9 entries
  • “roxadustat”, 8 entries
  • “ASP1517”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.